Business
ENDRA Life Sciences Provides Business Update and Reports Fourth Quarter and Full Year 2019 Financial Results
ANN ARBOR, MI / ACCESSWIRE / March 26, 2020 / ENDRA Life Sciences Inc. ("ENDRA") (NASDAQ:NDRA), the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS™),
About this update from Endra Life Sciences Inc.
[{"type":"text","content":"ANN ARBOR, MI / ACCESSWIRE / March 26, 2020 / ENDRA Life Sciences Inc. (\"ENDRA\") (NASDAQ:NDRA), the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS™), today provided a business update and reported fourth quarter and full year 2019 financial results.\"I am proud of the many, notable achievements ENDRA has made over the last year, which have given us strong forward momentum as we move towards our goal of bringing our breakthrough liver fat measurement application of the TAEUS technology to the EU and U.S. markets,\" said Francois Michelon, Chairman and Chief Executive Officer. \"Like others in our industry, we continue to monitor and evaluate the near and long term potential impacts of the COVID19 pandemic, and are making required adjustments to ensure ENDRA remains well positioned to deliver on our plans.\"Key 2019 HighlightsSubmitted CE Mark technical file for TAEUS liver device in the EU.Completed two-part, first in-human feasibility study of TAEUS liver application at Robarts Research Institute and reported top-line results.Announced new clinical study partnerships with two leading clinical institutions.Expanded leadership team with new Chief Commercial Officer, Renaud Maloberti, and Vice President of Engineering and Programs, Amy Sitzler.Increased intellectual property portfolio to 64 filed, issued and licensed patents and pending patent applications.Subsequent Events in Q1 2020Received CE Mark Approval for TAEUS FLIP (Fatty Liver Imaging Probe) System targeting Non-Alcoholic Fatty Liver Disease (\"NAFLD\") and Non-Alcoholic Steatohepatitis (\"NASH\").Renewed collaboration agreement with the GE Healthcare unit of General Electric Company (\"GE\"), extending the agreement's term to January 2021.Expanded Scientific Advisory Board with the addition of Raza Malik, M.D., Director of Hepatology and Associate Chief of the Division of Gastroenterology at Tufts Medical Center in Boston.\"Results generated from our feasibility study in 2019 and strong clinical reception to our ongoing pre-commercial activities have reinforced our excitement about the potential for the TAEUS liver fat application. We continue to believe it is well positioned to address a significant clinical need and technology gap for a safe, non-invasive, cost-effective and point-of-care tool to assess liver fat in patients with chronic liver conditions like N...